Regeneron Pharmaceuticals 8-K 2012
Pursuant to Section 13 or
15(d) of the
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
This Current Report on Form 8-K/A is being filed to amend the Current Report on Form 8-K filed by Regeneron Pharmaceuticals, Inc. (Regeneron) on November 22, 2011 (the Original Report). On November 18, 2011, the Board of Directors of Regeneron (the Board) elected Marc Tessier-Lavigne, Ph.D. as a director of Regeneron. This election was reported in the Original Report. At the time of the filing of the Original Report, board committee appointments for Dr. Tessier-Lavigne had not yet been determined. The sole purpose of this report is to disclose this information that was not determined at that time.
On January 20, 2012, the Board appointed Marc Tessier-Lavigne, Ph.D to the Compensation Committee and the Technology Committee.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.